Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STRIDE-1: AXS-05 in Treatment Resistant MDD
NCT02741791Phase 3Completed
- Sponsor
- Axsome Therapeutics, Inc.
- Start
- Mar 2016
- Primary completion
- Mar 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of dextromethorphan + bupropion in major depressive disorder (MDD), sponsored by Axsome Therapeutics, Inc.. Started Mar 2016; status: completed.
02
Drugs
dextromethorphan + bupropion
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT02741791.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02741791.